Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial

Annals of Oncology

Volumn 27, Issue 8, 2016, Pages 1579-1585

  Keefe, S M ^a   Hoffman Censits, J ^b   Cohen, R B ^a   Mamtani, R ^a   Heitjan, D ^c   Eliasof, S ^d   Nixon, A ^e   Turnbull, B ^f   Garmey, E G ^d   Gunnarsson, O ^g   Waliki, M ^a   Ciconte, J ^a   Jayaraman, L ^d   Senderowicz, A ^d   Tellez, A B ^d   Hennessy, M ^d   Piscitelli, A ^d   Vaughn, D ^a   Smith, A ^a   Haas, Naomi B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c SOUTHERN METHODIST UNIVERSITY   (United States)

^d Cerulean Pharma Inc   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BioBridges   (United States)

^g LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Angiogenesis; CRLX101; Hypoxia inducible factor; Nanoparticle drug conjugate; Recommended phase II dose; Renal cell carcinoma

Indexed keywords

ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CAMPTOTHECIN; CRXL 101; FIBROBLAST GROWTH FACTOR; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR BB; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLODEXTRIN; IT-101; MONOCLONAL ANTIBODY; NANOPARTICLE; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; BLOATING; CHILL; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CORRELATIONAL STUDY; CYSTITIS; DEHYDRATION; DENTAL CARIES; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; FLATULENCE; HEADACHE; HEARING IMPAIRMENT; HEMATURIA; HICCUP; HUMAN; HYPERPIGMENTATION; HYPOALBUMINEMIA; HYPOCALCEMIA; KIDNEY METASTASIS; LEUKOCYTE COUNT; LIMB PAIN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; ORAL MUCOSITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; SIDE EFFECT; SMELLING; THRUSH; TUMOR REGRESSION; URINARY FREQUENCY; URINARY TRACT INFECTION; VOICE CHANGE; VOMITING; WEIGHT REDUCTION; ADVERSE DRUG REACTION; CHEMISTRY; CLASSIFICATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; RENAL CELL CARCINOMA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CARCINOMA, RENAL CELL; CYCLODEXTRINS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NANOPARTICLES; PROTEIN KINASE INHIBITORS;

EID: 84984977897     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw188     Document Type: Article

References (23)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1): 5.
2. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170(6 Pt 1): 2163-2172.
3. National Cancer Institute. Drugs Approved in Kidney Cancer. Bethesda, MD: National Cancer Institute, http://www.cancer.gov/about-cancer/treatment/drugs/ kidney (1 September 2015, date last accessed).
4. Clark AJ, Wiley DT, Zuckerman JE et al. CRLX101 nanoparticles localize in human tumors andnot in adjacent, nonneoplastic tissue after intravenous dosing. Proc Natl Acad Sci USA 2016.
5. Eliasof S, Lazarus D, Peters CG et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci USA 2013; 110(37): 15127-15132.
6. Lou JJ, Chua YL, Chew JG et al. Inhibition of hypoxia-inducible factor-1alpha (HIF- 1alpha) protein synthesis by DNA damage inducing agents. PLoS One 2010; 5(5): e10522.
7. Ceruleanrx IB, www.ceruleanrx.com.
8. Pham E, Birrer MJ, Eliasof S et al. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res 2015; 21(4): 808-818.
9. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-247.
10. Weiss GJ, Chao J, Neidhart JD et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 2013; 31(4): 986-1000.
11. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-456.
12. Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012; 9(7): 378-390.
13. Rapisarda A, Hollingshead M, Uranchimeg B et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009; 8(7): 1867-1877.
14. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358(19): 2039-2049.
15. Kummar S, Raffeld M, Juwara L et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1a in advanced solid tumors. Clin Cancer Res 2011; 17(15): 5123-5131.
16. Rapisarda A, Zalek J, Hollingshead M et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004; 64 (19): 6845-6848.
17. Fizazi K, Rolland F, Chevreau C et al. A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer 2003; 98(1): 61-65.
18. Haas NB, Lin X, Manola J et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2012; 29 (2): 761-767.
19. Hainsworth JD, Shipley DL, Reeves J Jr et al. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Genitourin Cancer 2013; 11(3): 283-289.
20. Motzer RJ, Porta C, Vogelzang NJ et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15(3): 286-296.
21. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19): 1803-1813.
22. Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19): 1814-1823.
23. Voss M, Coates A, Garmey E et al. Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC). J Clin Oncol 2015; 33 (Suppl): abstr TPS4579.